Multicenter Phase II Study of Intraoperative Radiotherapy of Early Breast Cancer: Ipsilateral Tumor Recurrence

Masataka Sawaki(Aichi Cancer Center), Hiroji Iwata(Aichi Cancer Center), Toyone Kikumori(Nagoya University Hospital), Takeshi Kodaira(Aichi Cancer Center), Tomomi Fujisawa(The University of Osaka), Yoshiyuki Itoh(Nagoya University), Hiroyuki Tachibana(Aichi Cancer Center), Takeshi Miyamoto(Kumamoto Health Science University), Yasuhiro Yanagita(Hyogo Prefectural Cancer Center), Takeshi Ebara(Hyogo Prefectural Cancer Center)
Annals of Surgical Oncology
April 16, 2019
10.1245/s10434-019-07350-7
Cited by 18

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
|The Lancet|2020|1.1k